Estrella Immunopharma Expands STARLIGHT-1 Trial with New Texas Clinical Site
On Thursday, Estrella Immunopharma Inc. (NASDAQ:ESLA) announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial.
Estrella Immunopharma Inc. (ESLA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 3,975,220 | $4,134,229 | -4% | 0.05% |
| 2. | Renaissance Technologies Jim Simons | 39,100 | $40,664 | -38% | 0% |
| 3. | 87,500 | $12,460 | 0% | ||
| 4. | 42,293 | $5,498 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.33 | 1,000 | $1,330.00 | 265,488 | 2025-10-07 | Filing | |
| $1.16 | 1,000 | $1,160.00 | 16,700 | 2025-09-22 | Filing | |
| $1.04 | 100 | $104.00 | 264,588 | 2025-09-11 | Filing | |
| $314,700.00 | 141,970 | $44,677,959,000.00 | 1,253,730 | 2022-03-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 416,852 | $433,526 | 0% | |
| 2. | 189,899 | $197,495 | 0% | |
| 3. | 141,321 | $146,973 | 0% | |
| 4. | 64,921 | $67,518 | 0% | |
| 5. | 52,033 | $54,114 | 0% |
News See All
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial
Estrella Immunopharma, Inc.
Hedge Fund Resource Center